Related Experiment Video
Updated: Oct 6, 2025
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy
Xiaojuan Zhang1, Chuanchuan He1, Guangya Xiang1
1School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Abstract:
Hypoxia-inducible factor-1 (HIF-1), an essential promoter of tumor progression, has attracted increasing attention as a therapeutic target. In addition to hypoxic cellular conditions, HIF-1 activation can be triggered by cancer treatment, which causes drug tolerance and therapeutic failure. To date, a series of effective strategies have been explored to suppress HIF-1 function, including silencing the HIF-1α gene, inhibiting HIF-1α protein translation, degrading HIF-1α protein, and inhibiting HIF-1 transcription. Furthermore, nanoparticle-based drug delivery systems have been widely developed to improve the stability and pharmacokinetics of HIF-1 inhibitors or achieve HIF-1-targeted combination therapies as a nanoplatform. In this review, we summarize the current literature on nanomedicines targeting HIF-1 to combat cancer and discuss their potential for future development.
Insights
Hypoxia-inducible factor-1 (HIF-1) drives tumor growth and treatment resistance. Nanomedicines offer promising strategies to target HIF-1, enhancing cancer therapy by improving drug delivery and enabling combination treatments.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Hypoxia-inducible factor-1 (HIF-1) is crucial for tumor progression and survival.
- HIF-1 activation by cancer treatments can lead to drug resistance and therapeutic failure.
- Targeting HIF-1 presents a significant therapeutic opportunity in oncology.
Purpose of the Study:
- To review current nanomedicine strategies for targeting HIF-1 in cancer treatment.
- To explore the potential of nanoplatforms for delivering HIF-1 inhibitors.
- To discuss the development of nanoparticle-based HIF-1 targeted combination therapies.
Main Methods:
- Review of existing literature on nanomedicines targeting HIF-1.
- Analysis of strategies for suppressing HIF-1 function (gene silencing, protein inhibition/degradation, transcription inhibition).
- Evaluation of nanoparticle-based drug delivery systems for HIF-1 inhibitors.
Main Results:
- Various strategies exist to inhibit HIF-1, including genetic, translational, and transcriptional approaches.
- Nanoparticle drug delivery systems enhance HIF-1 inhibitor stability and pharmacokinetics.
- Nanomedicines facilitate targeted combination therapies against cancer via HIF-1.
Conclusions:
- Nanomedicines targeting HIF-1 are a developing area with significant potential in cancer therapy.
- Future research should focus on optimizing nanoplatforms for effective HIF-1 inhibition and combination treatments.
- Targeting HIF-1 with nanomedicine offers a promising avenue to overcome cancer drug resistance.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...